J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
An overview of early investigational therapies for chemoresistant ovarian cancer
TL;DR: An overview of early investigational drugs for the treatment of ‘platinum-resistant’ EOC is provided, based on English peer-reviewed articles located on MEDLINE and related abstracts presented at major international meetings.
Journal ArticleDOI
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
C. Sessa,Judith Balmaña,Sharon L. Bober,Maria João Cardoso,Nicoletta Colombo,Giuseppe Curigliano,S. Domchek,D. Gareth Evans,Daniela Fischerova,Nadia Harbeck,Christine Kuhl,Birthe Lemley,Efrat Levy-Lahad,Matteo Lambertini,Jonathan A. Ledermann,S. Loibl,Kelly-Anne Phillips,Paluch Shimon +17 more
TL;DR: In this paper , the authors defined hereditary breast and ovarian cancer syndrome (HBOC) by family history criteria and molecularly defined by identification of germline pathogenic variants (PVs) in clinically validated HBOC genes.
Journal ArticleDOI
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Osnat Elyashiv,Jonathan A. Ledermann,Gita Parmar,Laura Farrelly,Nicholas Counsell,Amanda Feeney,Fatima El-Khouly,Ian Macdonald,Andreia Neto,Esther Arthur-Darkwa,Eva Burnett,Gordon C Jayson,Linda Mileshkin,Charlie Gourley,Shibani Nicum +14 more
TL;DR: The aim of ICON9 is to investigate the combination of cediranib and olaparib maintenance in recurrent ovarian cancer following platinum-based therapy in women with platinum-sensitive ovarian, fallopian tube or peritoneal cancer during first relapse.
Journal ArticleDOI
Primary Chemotherapy for Inoperable Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without Delayed Debulking Surgery
Antonio Saha,Mohini A. Varughese,Chris J. Gallagher,George Orphanos,Peter Wilson,David H. Oram,Arjun R. Jeyarajah,K. Reynolds,John H. Shepherd,Mary McCormack,Adeola Olaitan,Nicola McDonald,Tim Mould,Iain A. McNeish,Jonathan A. Ledermann +14 more
TL;DR: Suboptimal debulking surgery after primary chemotherapy did not result in a better survival than that achieved after a chemotherapy response alone, suggesting that surgery may be avoided when imaging after chemotherapy demonstrates residual disease that cannot be optimally debulked.
Journal ArticleDOI
OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).
Helen Mackay,Christopher J. Gallagher,Wendy R. Parulekar,Jonathan A. Ledermann,Deborah K. Armstrong,Charlie Gourley,Ignacio A. Romero,Amanda Feeney,Paul Bessette,Marcia Hall,Johanne I Weberpals,Geoff Hall,S. Lau,Philippe Gauthier,Michael Fung-Kee-Fung,Elizabeth Eisenhauer,Chad Winch,Dongsheng Tu,Diane Provencher +18 more
TL;DR: A planned DSMC review confirmed dropping ARM2 (IP cis) and continuing study as an expanded phase II comparing 200 patients randomized to ARMs 1 and 3, which has 80% power to detect a 19% difference in progression rate at 9 mo.